⚠ Evidence warning: Clinical trials or other evidence do not support the claims that barberry or berberine relieves symptoms after gallbladder removal, helps primary biliary cholangitis and primary sclerosing cholangitis, prevents gallstones, and protects the liver during long-term acetaminophen use or aflatoxin exposure. This page keeps it as a report of what people, websites or other media say.

Barberry for Liver Health

Persian medicine called barberry root (Berberis vulgaris) zereshk and used it for at least a thousand years to treat hepatitis, jaundice, and what would now be called biliary stasis. The traditional reputation is supported by modern data: berberine and barberry whole-plant extracts demonstrate hepatoprotection against acetaminophen, carbon tetrachloride, and alcohol toxin models; act as cholagogues that stimulate bile flow and improve gallbladder emptying; reduce hepatic triglyceride content and serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) in non-alcoholic fatty liver disease (NAFLD) trials at standardized berberine doses; and show benefit in adjunctive treatment of viral hepatitis through immunomodulation and direct anti-fibrotic mechanisms. The open-label Yan 2015 PLOS ONE trial of 500 mg berberine three times daily plus lifestyle advice in 184 people with non-alcoholic fatty liver disease reported a 52.7% reduction in liver fat on magnetic resonance spectroscopy over 16 weeks, against 36.4% with lifestyle advice alone, with greater improvements in body weight, insulin resistance, and blood lipids. This page covers the historical context, the cholagogue and hepatoprotective mechanisms, the modern non-alcoholic fatty liver disease trial data, viral hepatitis applications, gallbladder and biliary tract effects, and the practical clinical integration of barberry into liver-supportive protocols.


Table of Contents

  1. Persian Medicine and the Zereshk Tradition
  2. Hepatoprotection — the Cellular Mechanisms
  3. Cholagogue Action — Bile Flow Stimulation
  4. Non-Alcoholic Fatty Liver Disease — the Yan 2015 Trial and Subsequent Evidence
  5. Non-Alcoholic Fatty Liver Disease — Why Berberine Reverses Hepatic Steatosis
  6. Viral Hepatitis — B and C Adjunct Use
  7. Alcohol-Related Liver Disease
  8. Toxin-Induced Liver Injury (Acetaminophen, Aflatoxin, Industrial)
  9. Cirrhosis, Fibrosis, and the Anti-Fibrotic Hypothesis
  10. Gallbladder Sludge, Biliary Insufficiency, and Stone Prevention
  11. Combining Barberry with Milk Thistle, N-Acetylcysteine, and Other Liver Herbs
  12. Dosing Protocols for Liver Indications
  13. Cautions and Drug Interactions
  14. Key Research Papers
  15. Connections
  16. Featured Videos

Persian Medicine and the Zereshk Tradition

The Persian medical tradition recognized barberry root (zereshk or zarrishk) as one of its primary "liver herbs" for at least 1,000 years. The classical Persian materia medica texts of Avicenna (The Canon of Medicine, 11th century) and Razi (Al-Hawi, 10th century) both describe zereshk root preparations for hepatitis ("inflammation of the liver"), jaundice ("yellowing of the eyes and skin"), and "obstruction of the liver" — a category that in modern terms covers biliary stasis, gallbladder sluggishness, and fatty liver. The Persian tradition also recognized barberry's antimicrobial and digestive effects but emphasized the liver application above all others.

The clinical observations underlying the tradition were remarkably accurate. The 11th-century Persian description of "obstruction of the liver" causing "torpor of digestion, yellowing of complexion, dark urine, and pale stools" maps closely onto modern descriptions of cholestatic and biliary disease. The Persian recommendation to treat such patients with barberry root decoction (with optional addition of saffron, fennel, and chicory root, all of which have their own modern-validated cholagogue or hepatoprotective effects) anticipates the modern combination of bitters and cholagogues used in functional medicine biliary protocols.

Persian cuisine also retained zereshk as a culinary ingredient — the dried red berries are scattered on saffron rice in the classical dish zereshk polo, often paired with chicken or lamb. The medicinal effect of the berry is much milder than the root because berberine is concentrated in the root bark, not the fruit. But the culinary use ensured that barberry remained part of household life and that low-dose dietary exposure to berberine was an everyday phenomenon in Persian households for centuries.

The Persian liver-medicine tradition was adopted into Greek and Arabic medicine and from there into European herbalism. Medieval European herbals describe barberry preparations for "jaundice and yellowness" using language that traces directly back to the Persian sources. The herb became less prominent in Western medicine in the 20th century but remained important in Ayurveda (where Berberis aristata, Indian barberry, is the local equivalent) and Traditional Chinese Medicine (where Coptis chinensis, with the same alkaloid berberine, fills a similar role).

The modern revival of berberine as a cardiometabolic and hepatic herb is, in this sense, not a discovery but a recovery — the molecule and its source plants have been used for liver indications continuously for a millennium in Persian, Arabic, and Asian medical traditions.

Back to Table of Contents

Hepatoprotection — the Cellular Mechanisms

Berberine's hepatoprotective action operates through multiple converging cellular mechanisms:

  1. Antioxidant action and Nrf2 pathway activation — berberine activates the Nrf2 transcription factor, which upregulates expression of phase II detoxification enzymes (glutathione S-transferase, NAD(P)H quinone dehydrogenase 1 (NQO1), heme oxygenase-1) and the cellular glutathione synthesis machinery. This shifts the liver's redox balance toward greater capacity for neutralizing oxidative damage from drugs, alcohol, and metabolic toxins.
  2. AMP-activated protein kinase (AMPK) activation and lipogenesis suppression — the same AMP-activated protein kinase mechanism described in the Blood Sugar deep-dive reduces hepatic de novo lipogenesis through inhibition of acetyl-CoA carboxylase (ACC). Less de novo fatty acid synthesis means less hepatic triglyceride accumulation, which is the central driver of non-alcoholic fatty liver disease pathology.
  3. Anti-inflammatory effect (NF-κB pathway suppression) — berberine inhibits the NF-κB transcription factor, reducing transcription of pro-inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6, interleukin-1 beta (IL-1β)) that drive chronic hepatic inflammation in non-alcoholic fatty liver disease, alcoholic liver disease, and viral hepatitis. Reduced hepatic inflammation slows progression to fibrosis and cirrhosis.
  4. Direct inhibition of hepatic stellate cell activation — hepatic stellate cells are the primary fibrogenic cell type in the liver; their activation from quiescent vitamin-A-storing cells into myofibroblast-like cells drives collagen deposition and fibrosis. Berberine inhibits stellate cell activation through TGF-β/Smad pathway interference, with implications for fibrosis prevention in chronic liver disease.
  5. Apoptosis modulation — berberine reduces hepatocyte apoptosis in toxin-injury models by stabilizing mitochondrial membrane potential and preventing cytochrome c release. This is one of the mechanisms behind protection against acetaminophen-induced liver injury (see below).
  6. Restoration of normal bile acid metabolism — berberine modifies the gut microbiome (see the Antimicrobial deep-dive) in ways that restore healthy secondary bile acid profiles, which signal through hepatic FXR and TGR5 receptors to regulate lipid and glucose metabolism and to reduce hepatic inflammation.

The combination of these mechanisms makes berberine a true multi-target hepatic agent — it addresses the four main pillars of chronic liver disease pathology (oxidative stress, inflammation, fibrosis, lipid accumulation) simultaneously rather than through a single molecular target.

Back to Table of Contents

Cholagogue Action — Bile Flow Stimulation

Cholagogues are agents that stimulate bile flow from the liver into the gallbladder and from the gallbladder into the duodenum. Berberine and barberry whole-plant extracts have been classically classified as cholagogues, and modern data confirms the effect through several mechanisms:

The clinical relevance of the cholagogue effect:

Back to Table of Contents

Non-Alcoholic Fatty Liver Disease — the Yan 2015 Trial and Subsequent Evidence

Non-alcoholic fatty liver disease (NAFLD) was renamed in 2023, by a multisociety consensus of liver associations, metabolic dysfunction-associated steatotic liver disease (MASLD); its inflamed form, formerly non-alcoholic steatohepatitis (NASH), is now metabolic dysfunction-associated steatohepatitis (MASH). It is the hepatic manifestation of metabolic syndrome and is the most common chronic liver disease in the developed world: a 2025 review estimates that 38% of all adults and 7-14% of children and adolescents now have it, and projects more than 55% of adults by 2040. A subset progresses to steatohepatitis (NASH/MASH), fibrosis, cirrhosis, and hepatocellular carcinoma. Until 2024 the U.S. Food and Drug Administration had approved no drug for the disease. Resmetirom was approved in 2024 for MASH with stage 2-3 fibrosis, and semaglutide followed in 2025 (see below); for fatty liver without that stage of fibrosis, lifestyle modification and off-label use of metabolic agents remain the mainstays of treatment.

The Yan et al. 2015 PLOS ONE trial is the most informative clinical evidence for berberine in non-alcoholic fatty liver disease. The trial was open-label (patients and doctors knew which treatment was given) and ran in three medical centres in China. It randomized 184 non-alcoholic fatty liver disease patients who also had impaired glucose regulation or type 2 diabetes to one of three arms for 16 weeks:

The primary endpoint was hepatic triglyceride content (HTGC) measured by proton magnetic resonance spectroscopy ((1)H-MRS), the most quantitative non-invasive measure of hepatic steatosis. Results:

Compared with LSI alone, berberine gave greater improvements in body weight, insulin resistance (homeostatic model assessment of insulin resistance, HOMA-IR), and blood lipids, and a greater fall in alanine aminotransferase. Compared with LSI + pioglitazone 15 mg, berberine was better only for body weight (4.3 kg lost vs 1.9 kg) and blood lipids; the falls in alanine aminotransferase and aspartate aminotransferase did not differ between the two drug arms. All three arms lost weight. Berberine side effects were mild and mainly digestive.

Subsequent meta-analyses have confirmed the basic findings. Wei et al. 2016 pooled six randomized controlled trials (RCTs) (501 non-alcoholic fatty liver disease patients total) and found significant berberine effects on alanine aminotransferase, total cholesterol, low-density lipoprotein (LDL), 2-hour blood glucose, and hemoglobin A1c; effects on triglycerides appeared only in subgroup analyses, and the authors called for more high-quality trials. A 2024 meta-analysis by Nie et al. pooled 10 randomized trials (811 people with fatty liver disease) and found that berberine lowered the liver enzymes alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase (GGT), along with triglycerides, total cholesterol, low-density lipoprotein, insulin resistance (HOMA-IR), and body mass index; high-density lipoprotein did not change significantly, and only mild stomach and bowel side effects were reported.

The second approved drug for the disease, semaglutide 2.4 mg once weekly, was approved for MASH in 2025 after the ESSENCE trial. In its first 800 patients with MASH and fibrosis stage 2 or 3, analysed at week 72, steatohepatitis resolved (without worsening fibrosis) in 62.9% on semaglutide vs 34.3% on placebo, and fibrosis improved (without worsening steatohepatitis) in 36.8% vs 22.4%; body weight fell 10.5% vs 2.0%. Stomach and bowel side effects were more common with semaglutide.

The collective non-alcoholic fatty liver disease evidence positions berberine as one of the most evidence-supported natural agents for hepatic steatosis reversal, with effect sizes that exceed lifestyle modification alone and, in the Yan trial, did not differ significantly from pioglitazone (a type 2 diabetes drug used off-label for fatty liver). For more on non-alcoholic fatty liver disease specifically, see our non-alcoholic fatty liver disease page and the NAFLD-MASLD Connection sub-article.

Back to Table of Contents

Non-Alcoholic Fatty Liver Disease — Why Berberine Reverses Hepatic Steatosis

Non-alcoholic fatty liver disease pathogenesis is now understood through the "multiple-hits hypothesis" — the disease results from convergence of insulin resistance, hepatic de novo lipogenesis, mitochondrial dysfunction, oxidative stress, lipotoxicity from accumulated intra-hepatic free fatty acids, inflammation, gut dysbiosis, and (in some patients) genetic susceptibility (PNPLA3 variants are the strongest established genetic risk factor).

Berberine addresses several of these pathogenic hits simultaneously:

  1. Insulin resistance reversal — the AMP-activated protein kinase mechanism described in the Blood Sugar deep-dive. Improved hepatic insulin sensitivity reduces de novo lipogenesis (which is upregulated by insulin in the insulin-resistant liver, paradoxically).
  2. De novo lipogenesis suppression — berberine inhibits SREBP-1c (the master transcription factor for hepatic lipogenesis) and ACC (the rate-limiting enzyme). Less new fatty acid synthesis means less hepatic triglyceride accumulation.
  3. Increased fatty acid oxidation — AMP-activated protein kinase-mediated reduction in malonyl-CoA releases CPT1 inhibition, increasing mitochondrial fatty acid beta-oxidation. The combined effect of reduced synthesis plus increased oxidation drives net depletion of stored hepatic triglyceride.
  4. Anti-inflammatory effect — NF-κB suppression reduces the chronic low-grade hepatic inflammation that drives progression from simple steatosis to steatohepatitis.
  5. Gut microbiome modulation — the favorable shift in gut microbiome composition reduces bacterial endotoxin (lipopolysaccharide, LPS) translocation through the portal vein to the liver, reducing Kupffer cell activation and hepatic TLR4 signaling.
  6. Bile acid metabolism normalization — restored secondary bile acid profile signals through FXR to reduce hepatic lipogenesis and increase fatty acid oxidation through coordinated transcriptional programs.

The combination of mechanisms means berberine attacks non-alcoholic fatty liver disease from multiple angles simultaneously, which is consistent with the Yan trial finding that its liver-fat effect was at least comparable to that of the single-target agent pioglitazone.

Back to Table of Contents

Viral Hepatitis — B and C Adjunct Use

Berberine has been studied as an adjunct in chronic hepatitis B and C management in several small trials. The proposed mechanisms include:

The clinical evidence is more limited than for non-alcoholic fatty liver disease or diabetes. Most trials are small, Chinese, and use berberine as adjunct to standard antiviral therapy rather than as monotherapy. The general finding is that adding berberine to standard hepatitis therapy modestly improves alanine aminotransferase/aspartate aminotransferase normalization, may improve viral load reduction, and reduces side effects of interferon-based regimens (which are now largely obsolete in the era of direct-acting antivirals for hepatitis C).

For acute viral hepatitis (hepatitis A, acute hepatitis B/C, or other), the Persian-medicine tradition of barberry root decoction may have symptom-relieving and hepatoprotective benefit, but is not a substitute for appropriate viral diagnosis and conventional medical management. For more on viral hepatitis, see our Hepatitis page, Hepatitis B page, and Hepatitis C page.

Back to Table of Contents

Alcohol-Related Liver Disease

Alcohol-related liver disease spans a spectrum from steatosis (fatty liver, reversible with abstinence) to alcoholic steatohepatitis to fibrosis, cirrhosis, and decompensated liver failure. Berberine has been studied in animal models of alcohol-induced liver injury with consistent hepatoprotective findings:

Human clinical data is more limited but generally consistent. Berberine is proposed as an adjunct in early alcohol-related liver disease; alcohol abstinence is by far the most important intervention. The cholagogue effect may also help with the digestive symptoms that often accompany alcohol-related liver disease.

The combination of berberine + milk thistle (silymarin) + N-acetylcysteine (NAC) is a common functional medicine protocol for alcohol-related liver support and combines multiple mechanisms — AMP-activated protein kinase / lipogenesis suppression (berberine), glutathione precursor and direct antioxidant, and Nrf2-pathway antioxidant + hepatic protein synthesis support (silymarin). See our Milk Thistle page and N-acetylcysteine for Liver Health page.

Back to Table of Contents

Toxin-Induced Liver Injury (Acetaminophen, Aflatoxin, Industrial)

The classical experimental models of hepatotoxicity are acetaminophen overdose (the dominant cause of acute liver failure in the United States, with N-acetylcysteine as the established antidote) and carbon tetrachloride (a research-only solvent that produces reproducible centrilobular necrosis through cytochrome P450 bioactivation). Berberine and barberry extracts have demonstrated hepatoprotection in both models.

In the acetaminophen model, pretreatment with berberine reduces hepatic glutathione depletion, reduces alanine aminotransferase/aspartate aminotransferase elevation, reduces centrilobular necrosis on histology, and improves survival in lethal-overdose models. The proposed mechanism is partly through the Nrf2 / glutathione synthesis pathway (parallel to N-acetylcysteine's mechanism) and partly through direct attenuation of the inflammatory amplification that follows the initial hepatocyte injury.

The proposed clinical implication, untested in human trials, is that berberine may have a role as a long-term hepatoprotective adjunct for patients on chronic acetaminophen (e.g., chronic pain management with daily acetaminophen 1-2 grams) where the cumulative oxidative-stress burden on the liver is a concern. N-acetylcysteine is established for acute overdose; berberine for chronic low-dose exposure remains a proposal. See our N-acetylcysteine for Acetaminophen page for the acute-management protocol.

Aflatoxin (the carcinogenic mycotoxin produced by Aspergillus flavus growing on improperly stored grain and peanuts in tropical climates) is a major risk factor for hepatocellular carcinoma worldwide. Berberine has shown protective effects against aflatoxin-induced hepatic damage in animal studies, though human data is limited. Its use in populations with significant dietary aflatoxin exposure, as part of a broader hepatic-protection protocol, is proposed on the basis of these animal findings.

Industrial hepatotoxin exposure (carbon tetrachloride, chloroform, vinyl chloride, certain pesticides) is a less common but still clinically relevant concern in occupational medicine. Berberine demonstrates broad hepatoprotection in animal models of these exposures, primarily through the Nrf2 / glutathione pathway.

Back to Table of Contents

Cirrhosis, Fibrosis, and the Anti-Fibrotic Hypothesis

Hepatic fibrosis is the deposition of excess extracellular matrix (collagen, fibronectin, proteoglycans) in the liver in response to chronic injury, and it is the precursor to cirrhosis (the late-stage architectural distortion that defines end-stage liver disease). The cellular driver of fibrosis is activation of hepatic stellate cells from quiescent vitamin-A-storing cells into proliferative myofibroblast-like cells that produce collagen.

Berberine has demonstrated anti-fibrotic effects in multiple animal models of liver fibrosis (carbon tetrachloride, bile duct ligation, thioacetamide, dimethylnitrosamine):

Human evidence is more limited but emerging. Several Chinese trials have evaluated berberine as adjunct in chronic hepatitis B-associated fibrosis with promising findings, though the trial quality is variable. Western clinical guidelines do not currently recommend berberine for fibrosis prevention.

The mechanistic rationale is plausible: by reducing hepatic inflammation, restoring insulin sensitivity, reducing hepatic steatosis, and directly inhibiting stellate cell activation, berberine addresses multiple upstream drivers of fibrosis. The practical clinical question is whether the magnitude of effect in humans is sufficient to slow fibrosis progression meaningfully — a question that will require larger, longer trials to answer definitively.

Back to Table of Contents

Gallbladder Sludge, Biliary Insufficiency, and Stone Prevention

Gallbladder sludge is the precursor to gallstones — a viscous mixture of calcium bilirubinate, cholesterol microcrystals, and mucin that accumulates when bile flow is sluggish. Sustained bile stasis allows cholesterol nucleation into stones, particularly in patients with elevated cholesterol-to-bile-acid ratios in their bile.

Berberine's cholagogue effect plus its cholesterol-lowering effect together work against gallstone formation through several mechanisms:

Direct evidence for gallstone prevention from berberine clinical trials is limited, but the mechanistic case is strong. Herbal practitioners use low-dose barberry tincture taken before meals (or full-dose berberine for those with concurrent metabolic indications) as a preventive for people with documented biliary sludge, recurrent biliary colic, or a family history of gallstone disease; this use has not been tested in trials.

For patients post-cholecystectomy, the loss of regulated bile delivery often produces symptoms of bloating, fat-meal intolerance, and intermittent diarrhea. Practitioners describe a barberry tincture pre-meal protocol (40-60 drops of 1:5 tincture in water, 15 minutes before meals) as improving symptoms, proposing CCK-mediated sphincter of Oddi modulation and the digestive bitter effect as the mechanism — this is covered further in the Digestive Aid deep-dive.

Back to Table of Contents

Combining Barberry with Milk Thistle, N-Acetylcysteine, and Other Liver Herbs

Barberry / berberine is rarely the sole liver-supportive intervention in functional medicine practice. The common combinations, with the doses practitioners use:

Back to Table of Contents

Dosing Protocols for Liver Indications

The doses below are those used in the trials and practitioner protocols described on this page; the Yan trial used berberine 500 mg three times daily for 16 weeks.

Non-alcoholic fatty liver disease / non-alcoholic steatohepatitis (cardiometabolic dose).

Alcohol-related liver disease (adjunct to abstinence).

Viral hepatitis (adjunct to standard antiviral therapy).

Cholagogue / biliary insufficiency (digestive dose).

Hepatoprotection during chronic acetaminophen use.

Back to Table of Contents

Cautions and Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Yan HM et al. (2015). Efficacy of berberine in patients with non-alcoholic fatty liver disease. PLOS ONE, 10(8):e0134172. — the 16-week open-label NAFLD trial with liver fat measured by magnetic resonance spectroscopy. PubMed PMID: 26252777
  2. Wei X, Wang C, Hao S, Song H, Yang L (2016). The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Evidence-Based Complementary and Alternative Medicine, 2016:3593951. — PubMed PMID: 27446224
  3. Zhang Y, Li X, Zou D, et al. (2008). Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. Journal of Clinical Endocrinology and Metabolism, 93(7):2559-2565. — glycemic and lipid outcomes. PubMed PMID: 18397984
  4. Domitrović R, Jakovac H, Blagojević G (2011). Hepatoprotective activity of berberine is mediated by inhibition of TNF-α, COX-2, and iNOS expression in CCl(4)-intoxicated mice. Toxicology, 280(1-2):33-43. — toxin-protection model (carbon tetrachloride in mice). PubMed PMID: 21095217
  5. Sun Y, Xia M, Yan H, et al. (2018). Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21. British Journal of Pharmacology, 175(2):374-387. — mechanism of hepatic steatosis reversal (mice). PubMed PMID: 29065221
  6. Imanshahidi M, Hosseinzadeh H (2008). Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytotherapy Research, 22(8):999-1012. — comprehensive Berberis vulgaris review including hepatic indications. PubMed PMID: 18618524
  7. Nie Q, Li M, Huang C, Yuan Y, Liang Q, Ma X, Qiu T, Li J (2024). The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review. Journal of Translational Medicine, 22(1):225. — recent meta-analysis. PubMed PMID: 38429794
  8. Habtemariam S (2020). Berberine pharmacology and the gut microbiota: A hidden therapeutic link. Pharmacological Research, 155:104722. — gut-liver axis link. PubMed PMID: 32105754
  9. Rinella ME, Lazarus JV, Ratziu V, et al. (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Journal of Hepatology, 79(6):1542-1556. — the NAFLD-to-MASLD renaming. PubMed PMID: 37364790
  10. Younossi ZM, Kalligeros M, Henry L (2025). Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology, 31(Suppl):S32-S50. — current prevalence. PubMed PMID: 39159948
  11. Sanyal AJ, Newsome PN, Kliers I, et al. (2025). Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. New England Journal of Medicine, 392(21):2089-2099. — the ESSENCE trial. PubMed PMID: 40305708
  12. Qasim A, Alataa R, Veena F, Shehi E (2026). The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents. Frontiers in Gastroenterology, 5:1850915. — resmetirom and semaglutide approvals. PubMed PMID: 42564069

PubMed Topic Searches

  1. PubMed: Berberine NAFLD
  2. PubMed: Berberine hepatoprotection
  3. PubMed: Berberis vulgaris hepatic
  4. PubMed: Berberine hepatitis B/C
  5. PubMed: Berberine fibrosis / stellate cells
  6. PubMed: Berberine cholagogue bile flow

Back to Table of Contents

Connections

Back to Table of Contents